News
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, as well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.
Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.
As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.
Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
In Case You Missed It: Krakatoa soars on thick King Tamba pegmatites in big day for resources stocks
Health & Biotech
ASX Health Stocks: Race Oncology gets certified for RC220; human trials next
News
In Case You Missed It: New gold licence for Mantle, Stelar Metals to start lithium drill program
Health & Biotech
Race Oncology releases ‘striking’ interim Phase 2 AML trial results
News
Closing Bell: ASX has best week ever… or at least since everything crashed last month. So… wait… damn you Friday!
Explainers
ASX cancer stocks guide: Here’s everything you need to know
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Experts
MoneyTalks: Merchant Group’s Andrew Chapman has his eye on these diagnostic biotech stocks
Health & Biotech
Race Oncology’s fresh corporate strategy puts it right at the heart of cancer care
Health & Biotech
ASX Health Stocks: Recce Pharma jumps 20pc after saying its gel could heal antibiotic-resistant infections
Health & Biotech
ASX Health Stocks: Bod Science provides ‘landmark update’, while Incannex prepares to list on Nasdaq
Health & Biotech
Orphan drug designation has a direct impact on drug pricing for these pharma players
Health & Biotech
ASX Health Stocks: Paradigm shows good Phase 2 results, Race Oncology jumps 8pc after third party report on Zantrene
News
CLOSING BELL: Brace yourselves… even the clowns in charge don’t know what’s coming.
News
Top 10 at 10: Which gold explorer is glittering today after positive results from drilling program?
News
CLOSING BELL: Goldies cop a beating as investors race back into the arms of the risk monster
Health & Biotech